Akorn Enters Supply Agreement with X-Gen

Akorn, Inc. has signed a commercial manufacturing supply agreement with X-Gen Pharmaceuticals for Neomycin and Polymyxin B Sulfates Solution for Irrigation USP. The FDA recently approved x-Gen’s Neomycin and Polymyxin B Sulfates Solution for Irrigation USP as an ANDA. Akorn’s Decatur, IL manufacturing facility, with capabilities to produce sterile injectables, ophthalmics, and lyophilized pharmaceuticals, is the approved manufacturing site for this product.

Arthur S. Przybyl, Akorn’s president and chief executive officer stated, “Our contract product development and manufacturing business segment is an exciting growth area for the company. Akorn is pleased to be a strategic partner with X-Gen in the manufacturing of this product.”

X-Gen president and chief executive officer Susan Badia stated, “The addition of this product to our offering is another example of X-Gen’s long standing tradition and commitment to provide affordable drug therapy options to the healthcare community. We are pleased to have a manufacturing partnership with Akorn as we continue serving the healthcare community as a preferred source for generic choices, including Neomycin and Polymyxin B Sulfates Solution for Irrigation USP.”